Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.

Marathe CS, Pham H, Wu T, Trahair LG, Rigda RS, Buttfield MDM, Hatzinikolas S, Lange K, Rayner CK, Mari A, Horowitz M, Jones KL

Diabetes therapy : research, treatment and education of diabetes and related disorders22 Apr 2022Cited by 7 (Europe PMC)

PMID35460043PMCIDPMC9174387DOI10.1007/s13300-022-01258-4PepBankPUB-35460043

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialMechanism
In healthy participants, lixisenatide slowed gastric emptying versus placebo from 1.45 ± 0.10 to 0.60 ± 0.14 kcal/min.
In plain wordsIn healthy participants, lixisenatide slowed stomach emptying versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseGastric emptying in healthy participants
Study
n = 15
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10 μg · subcutaneousAs given in this study (human).
Measurements
Gastric emptying rate
1.45 kcal/min
healthy subjects, placebo
Gastric emptying rate
0.6 kcal/min
healthy subjects, lixisenatide
Source sentences
Summary
GE was markedly slowed by lixisenatide compared with placebo in both healthy subjects (1.45 ± 0.10 kcal/min for placebo vs. 0.60 ± 0.14 kcal/min for lixisenatide) and diabetes (1.57 ± 0.06 kcal/min for placebo vs. 0.75 ± 0.13 kcal/min for lixisenatide) (both P < 0.001) with no difference between the…
1 context sentence(design, population, supporting numbers)
Summary · context
All subjects received lixisenatide (10 μg sc) or placebo in a randomised, double-blind, crossover fashion 30 min before the drink.
Report a problemFND-3546004301
02HumanRandomized controlled trialMechanism
In participants with diabetes, lixisenatide slowed gastric emptying versus placebo from 1.57 ± 0.06 to 0.75 ± 0.13 kcal/min.
In plain wordsIn participants with diabetes, lixisenatide slowed stomach emptying versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseGastric emptying in diabetes
Study
n = 15
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10 μg · subcutaneousAs given in this study (human).
Measurements
Gastric emptying rate
1.57 kcal/min
type 2 diabetes, placebo
Gastric emptying rate
0.75 kcal/min
type 2 diabetes, lixisenatide
Source sentences
Summary
GE was markedly slowed by lixisenatide compared with placebo in both healthy subjects (1.45 ± 0.10 kcal/min for placebo vs. 0.60 ± 0.14 kcal/min for lixisenatide) and diabetes (1.57 ± 0.06 kcal/min for placebo vs. 0.75 ± 0.13 kcal/min for lixisenatide) (both P < 0.001) with no difference between the…
1 context sentence(design, population, supporting numbers)
Summary · context
All subjects received lixisenatide (10 μg sc) or placebo in a randomised, double-blind, crossover fashion 30 min before the drink.
Report a problemFND-3546004302
03HumanObservational studyMechanism
Gastric emptying responses to lixisenatide did not differ significantly between healthy participants and participants with diabetes (P = 0.42).
In plain wordsThe stomach-emptying response to lixisenatide was similar in healthy participants and participants with diabetes.
Peptide
Lixisenatide
Outcome
No significant changeGastric emptying response by disease status
Study
n = 30
Comparator
Healthy participants
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
GE was markedly slowed by lixisenatide compared with placebo in both healthy subjects (1.45 ± 0.10 kcal/min for placebo vs. 0.60 ± 0.14 kcal/min for lixisenatide) and diabetes (1.57 ± 0.06 kcal/min for placebo vs. 0.75 ± 0.13 kcal/min for lixisenatide) (both P < 0.001) with no difference between the…
1 context sentence(design, population, supporting numbers)
Summary · context
All subjects received lixisenatide (10 μg sc) or placebo in a randomised, double-blind, crossover fashion 30 min before the drink.
Report a problemFND-3546004303
04HumanObservational studyMechanism
In healthy participants given lixisenatide, early insulin secretion correlated inversely with gastric retention at 60 min (r = -0.8, P = 0.0003).
In plain wordsIn healthy participants given lixisenatide, greater stomach retention was linked to lower early insulin secretion.
Peptide
Lixisenatide
Outcome
DecreaseInsulin secretion and gastric retention correlation in healthy participants
Study
n = 15
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10 μg · subcutaneousAs given in this study (human).
Measurements
Correlation, early insulin secretory response vs gastric retention at 60 min
−0.8 r
healthy subjects, lixisenatide
Source sentences
Summary
There was a moderate to strong inverse correlation between the early insulin secretory response calculated at 60 min and gastric retention at 60 min with lixisenatide treatment in healthy subjects (r = - 0.8, P = 0.0003)
1 context sentence(design, population, supporting numbers)
Summary · context
All subjects received lixisenatide (10 μg sc) or placebo in a randomised, double-blind, crossover fashion 30 min before the drink.
Report a problemFND-3546004304
05HumanObservational studyMechanism
In participants with diabetes given lixisenatide, insulin secretion showed a nonsignificant inverse trend with gastric retention (r = -0.4).
In plain wordsIn participants with diabetes given lixisenatide, greater stomach retention showed a nonsignificant link to lower early insulin secretion.
Peptide
Lixisenatide
Outcome
DecreaseInsulin secretion and gastric retention correlation in diabetes
Study
n = 15
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10 μg · subcutaneousAs given in this study (human).
Measurements
Correlation, early insulin secretory response vs gastric retention at 60 min
−0.4 r
type 2 diabetes, lixisenatide
Source sentences
Summary
There was a moderate to strong inverse correlation between the early insulin secretory response calculated at 60 min and gastric retention at 60 min with lixisenatide treatment in healthy subjects (r = - 0.8, P = 0.0003) and a trend in type 2 diabetes (r = - 0.4, P = NS),
1 context sentence(design, population, supporting numbers)
Summary · context
All subjects received lixisenatide (10 μg sc) or placebo in a randomised, double-blind, crossover fashion 30 min before the drink.
Report a problemFND-3546004305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 1/2NCT02308254

Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

Royal Adelaide Hospitaln = 30Nov 2013 to est. Apr 2016

Diabetes Mellitus · Gastroparesis

Trial page ClinicalTrials.govUpdated 29 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.